| Prev Close | 0.86 |
| Open | 0.86 |
| Day Low/High | 0.84 / 0.86 |
| 52 Wk Low/High | 0.80 / 1.34 |
| Volume | 113.20K |
| Avg Volume | 317.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 105.44M |
| Market Cap | 90.85M |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Management to hold a conference call at 10:00 a.m. EST
- AGI-134 on track to commence Phase 1/2a clinical study in H1 2018 -
- BL-8040 monotherapy resulted in increased infiltration of T cells into tumor -
Study will assess mobilization of hematopoietic stem cells by BL-8040 compared to placebo, on top of G-CSF, for autologous transplantation in multiple myeloma patients
BL-8040 in combination with high-dose Ara-C significantly improved overall survival compared to historical data
Enrollment to COMBAT study has been completed; full topline results expected in H2 2018 as planned
Management to hold a conference call at 10:00 a.m. EST
- Preclinical data demonstrate that BL-8040 mobilizes a significant number of these HSCs compared to G-CSF, thus potentially improving graft quality -
BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions...
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific...
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it will host an investor breakfast...
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the third...
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited...
BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive results from the dose...
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Omega Pharma,...
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the...
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a Phase 2b...
BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...
BioLineRx (BLRX) shares are down by almost 20% after the company confirmed weak results from its placebo-controlled heart disease treatment tests.
